Tokio Marine Asset Management Co. Ltd. Acquires 568 Shares of Eli Lilly and Company (NYSE:LLY)

Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,809 shares of the company’s stock after acquiring an additional 568 shares during the quarter. Eli Lilly and Company comprises approximately 1.5% of Tokio Marine Asset Management Co. Ltd.’s portfolio, making the stock its 11th biggest holding. Tokio Marine Asset Management Co. Ltd.’s holdings in Eli Lilly and Company were worth $27,869,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in LLY. Kirr Marbach & Co. LLC IN grew its position in shares of Eli Lilly and Company by 1.5% during the 3rd quarter. Kirr Marbach & Co. LLC IN now owns 5,782 shares of the company’s stock valued at $3,105,000 after purchasing an additional 88 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 113.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 6,195 shares of the company’s stock valued at $3,328,000 after purchasing an additional 3,295 shares in the last quarter. 1900 Wealth Management LLC grew its position in shares of Eli Lilly and Company by 28.3% during the 3rd quarter. 1900 Wealth Management LLC now owns 1,028 shares of the company’s stock valued at $552,000 after purchasing an additional 227 shares in the last quarter. Park Place Capital Corp grew its position in shares of Eli Lilly and Company by 19.5% during the 3rd quarter. Park Place Capital Corp now owns 3,041 shares of the company’s stock valued at $1,633,000 after purchasing an additional 496 shares in the last quarter. Finally, Eastern Bank grew its position in shares of Eli Lilly and Company by 155.9% during the 3rd quarter. Eastern Bank now owns 30,283 shares of the company’s stock valued at $16,266,000 after purchasing an additional 18,449 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Truist Financial reiterated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Bank of America upped their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Trading Down 1.8 %

Shares of NYSE:LLY traded down $13.49 during midday trading on Wednesday, hitting $732.20. 2,052,626 shares of the stock traded hands, compared to its average volume of 3,038,542. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78. The stock has a market capitalization of $695.71 billion, a PE ratio of 126.24, a P/E/G ratio of 1.59 and a beta of 0.34. The business’s 50 day moving average is $763.40 and its two-hundred day moving average is $664.52. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the firm earned $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. As a group, research analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.